Inspiremd announces completion of enrollment in c-guardians u.s. investigational device exemption (ide) clinical trial

Trial designed to support potential u.s. marketing approval of the cguard™ prime eps stent system study also included first-in-human cases treated with cguard prime cas stent delivery platform company anticipates study results and premarket approval (pma) submission in h2 2024, potential u.s. approval in h1 2025 tel aviv, israel, june 26, 2023 (globe newswire) -- inspiremd, inc. (nasdaq: nspr), developer of the cguard™ embolic prevention stent system (eps) for the prevention of stroke, today announced that it completed enrollment of its ongoing c-guardians u.s. investigational device exemption (ide) clinical trial, designed to support potential u.s. marketing approval of the cguard prime eps stent system. marvin slosman, chief executive officer of inspiremd, stated, “the completion of enrollment in our ide trial is a significant milestone and brings us one step closer to potential u.s. approval of the cguard prime eps stent system.
NSPR Ratings Summary
NSPR Quant Ranking